Clinical Trials Browser

Interventional × HER2-negative Breast Cancer × anlotinib × Clear all

NCT04624711 2021-05-21

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Unknown

HER2-negative Breast Cancer